Integrated Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease (MUGEN)
Immunological diseases encompass a wide variety of disorders, affecting a steadily increasing proportion of people living in modern societies. Immunological diseases include multiple sclerosis, systemic lupus, rheumatoid arthritis and cancer.During the past decade, dramatic advances have been made in understanding mechanisms regulating the immune system, its pathological processes, and processes of immune deviation. As such, it was recognized that systemic or organ-specific inflammatory, infectious and autoimmune conditions share basic mechanisms of initiation and progression. Further elucidation of these mechanisms promises to be of very high value for diagnosis and treatment of these disorders.
sPLA2-IID is a novel effector of regulatory T cells
03-06-2009. MUGEN partner Martin Bachmann's group at Cytos Biotechnology shed light to the mechanism of action of Tregs. The researchers show that secreted phospholipase A2 is selectively produced by natural Tregs and acts as a potent suppressor of T cell activation both in vitro and in vivo. The results will be published in the upcoming issue of PNAS
11-05-2009. 2nd International MUGEN Conference on Animal Models for Human Immunological Disease, 8-10 October, Athens, Greece MUGEN Workshop on Immune Mouse Phenotyping, 6-8 October 2009, Athens, Greece
IKK1 coordinates multiple BAFF-R-mediated pathways controlling B cell homeostasis
19-01-2009. MUGEN participants K. Rajewsky (CBR) and M. Pasparakis (Uni. Koeln) show in their recent paper in PNAS that BAFF-induced signaling pathways are mediated by BAFF-R and represent previously unknown arms of I kappa B kinase (IKK)1-dependent signaling.
sPLA2-IID is a novel effector of regulatory T cells
